JAK1 and myocarditis: In terms of early intervention, the latest study by the Joe-Elie SALEM team found that early management measures for ICI myocarditis patients, such as mechanical ventilation, high-dose Abatacept and Ruxolitinib (a JAK1/JAK2 inhibitor) treatment combined with CD86 RO (CD86 receptor occupancy on circulating monocytes) monitoring, hold promise for reducing the high mortality rate caused by ICI-induced myocarditis, but further research is still needed to evaluate the optimal drug combination and dosage [458].